tbuckley/cabot-search huggingface dataset:
Molecular and Clinical <i>PHF6</i> Mutant Myeloid Neoplasia Provides Clues As to Their Pathogenesis and Therapeutic Targeting
Authors: Yasuo Kubota, Laila Terkawi, Carmelo Gurnari, Juraj Bodo, Naomi Kawashima, Mai Aly, Arda Durmaz, Minako Mori, BEN Ponvilawan, Tariq Kewan, Waled Bahaj, Valeria Visconte, Heesun J. Rogers, Torsten Haferlach, Jaroslaw P. Maciejewski
Journal: Blood (2022)
Stem Cell-Derived Gene Expression Scores Predict Survival and Leukemic Transformation in Myelofibrosis
Authors: Jessie J.F. Medeiros, Andy G.X. Zeng, Michelle Chan-Seng-Yue, Tristan Woo, Jessica L McLeod, Andrea Arruda, Hubert Tsui, Burhan Goraya, Jaime O. Claudio, Jenny M. Ho, James A. Kennedy, Dawn Maze, Hassan Sibai, Mark D. Minden, Jean C.Y. Wang, John E. Dick, Vikas Gupta
Journal: Blood (2022)
Hematology Referral, Stroke Recurrence and Mortality Among Patients with First Ischemic Stroke and Polycythemia or Thrombocytosis
Authors: Marcelo Pitombeira de Lacerda, Aline da Silva Tezotto, Yves Gabriel Souza Roussenq, Carolina Werner, Gabriela da Costa Werlang, Iohana Vitória Dalri, Joao Pedro Ribeiro Baptista, Fernanda de Morais Marques, Juliana Safanelli, Vivian Nagel, Paulo Henrique Condeixa de Franca, Alexandre Luis Longo
Journal: Blood (2022)
Evaluation of High-Dose Cytarabine Induction Therapy and Flow Cytometric Measurable Residual Disease Monitoring for Children with <i>De Novo</i> Acute Myeloid Leukemia: A Report from the JPLSG-AML-12 Trial
Authors: Daisuke Tomizawa, Shiro Tanaka, Shotaro Iwamoto, Hidefumi Hiramatsu, Jun Matsubayashi, Daisuke Hasegawa, Hiroshi Moritake, Daiichiro Hasegawa, Kiminori Terui, Asahito Hama, Shin-ichi Tsujimoto, Nobutaka Kiyokawa, Hayato Miyachi, Takao Deguchi, Yoshiko Hashii, Yuka Iijima-Yamashita, Tomohiko Taki, Yasushi Noguchi, Kazutoshi Koike, Katsuyoshi Koh, Yuki Yuza, Akiko Moriya Saito, Keizo Horibe, Takashi Taga, Souichi Adachi
Journal: Blood (2022)
Using Spatial Transcriptomics to Reveal Fetal Liver Hematopoietic Stem Cell-Niche Interactions
Authors: Ruochen Dong, Jonathon Russell, Hua Li, Seth Malloy, Kate Hall, Kaitlyn Petentler, Allison Scott, Cathy Mckinney, Sarah E Smith, Yongfu Wang, Anoja Perera, Sean McKinney, Brian Slaughter, Jay Unruh, Xi C He, Linheng Li
Journal: Blood (2022)
Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV)
Authors: Jean-Jacques Kiladjian, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiří Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans Carl Hasselbalch, Robert Kralovics, Heinz Gisslinger
Journal: Blood (2022)
Extramedullary Hematopoiesis (EMH) and Myelodysplastic Syndrome (MDS): Review
Authors: Mahmood B Aldapt, Fadi Haddad, Tareq Abuasab, Dina Sameh Soliman, Feryal Abbas, Osama Mosalem, Ashraf Ahmed, Sara Saeed, Mohammad Abdul-Jaber Abdulla, Shehab Fareed Mohamed
Journal: Blood (2022)
The HOVON 100 Study in Adult Acute Lymphoblastic Leukemia Re-Analysed By Multi-State Modeling: Benefits and Risks of Clofarabine
Authors: Sjoerd J.F. Hermans, Yvette Norden, Jurjen Versluis, Anita W. Rijneveld, Okke De Weerdt, Bart J. Biemond, Arjan A. van de Loosdrecht, Lotte E. Van der Wagen, Mar Bellido, Michel Van Gelder, Walter J.F.M. Van der Velden, Dominik Selleslag, Danielle van Lammeren, Vincent H.J. van der Velden, Liesbeth C. de Wreede, Douwe Postmus, Francesco Pignatti, Jan J. Cornelissen
Journal: Blood (2022)
Iadademstat Combination with Azacitidine Is a Safe and Effective Treatment in First Line Acute Myeloid Leukemia. Final Results of the Alice Trial
Authors: Olga Salamero, Tim C.P Somervaille, Antonieta Molero, Evelyn Acuña-Cruz, Jose A. Perez-Simon, Rosa Coll, Montserrat Arnan, Brayan Merchan, Ana Perez, Isabel Cano, Rebeca Rodríguez-Veiga, Mabel Arevalo, Sonia Gutierrez, Carlos Buesa, Douglas V Faller, Francesc Bosch, Pau Montesinos
Journal: Blood (2022)
Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis
Authors: Haris Ali, Dongyun Yang, Sally Mokhtari, Timothy Synold, Idoroenyi Amanam, Andrew S. Artz, Peter T. Curtin, Karamjeet S. Sandhu, Anthony S. Stein, Shukaib Arslan, Salman Otoukesh, Firoozeh Sahebi, Joshua Mansour, Paul B. Koller, Amandeep Salhotra, Ibrahim Aldoss, Vinod A. Pullarkat, Brian J Ball, Stephen J Forman, Guido Marcucci, Monzr M. Al Malki, Ryotaro Nakamura
Journal: Blood (2022)
Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival
Authors: Farah Fleti, Amritpal Singh, Aref Al-Kali, James M. Foran, Michelle A Elliott, Kebede Begna, Talha Badar, Nandita Khera, Mithun V. Shah, Hassan B. Alkhateeb, Maymona Abdelmagid, Kaaren K. Reichard, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi
Journal: Blood (2022)
Comparable Long-Term Outcomes of Low-Dose Versus Standard-Dose Equine Anti-Thymocyte Globulin with Cyclosporine in Aplastic Anemia
Authors: Aditya Jandial, Charanpreet Singh, Deepesh Lad, Gaurav Prakash, Alka Khadwal, Reena Das, Neelam Varma, Subhash Varma, Pankaj Malhotra, Arihant Jain
Journal: Blood (2022)
Comparative Characteristics of the Effectiveness of Tyrosine Kinase Inhibitors Vs Allogeneic Hematopoietic Stem Cell Transplantation in the Chronic Phase of Chronic Myeloid Leukemia
Authors: Elza Lomaia, Tamara Chitanava, Yulia Vlasova, Dmitry Motorin, Sergey Voloshin, Darina Zammoeva, Renat Badaev, Yulia Matvienko, Elizaveta Efremova, Ekaterina Mileeva, Nadia Siordia, Olga Kulemina, Eugenia Sbityakova, Natalia Lazorko, Julia Alexeeva, Irina Martynkevich, Elena Karyagina, Natalia Ilyina, Nadezhda Medvedeva, Natalia Dorofeeva, Tatiana Shneider, Svetlana Stepanova, Vasily Shuvaev, Elena Morozova
Journal: Blood (2022)
Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia
Authors: Shlomo Elias, Moneeza Walji, Samantha Brown, Sean M. Devlin, Esperanza B. Papadopoulos, Ann A Jakubowski, Doris M Ponce, James W. Young, Sergio A Giralt, Miguel-Angel Perales, Brian C. Shaffer, Parastoo B. Dahi, Richard J. Lin, Christina Cho, Roni Tamari, Melody Smith, Boglarka Gyurkocza
Journal: Blood (2022)
Circulating B-Cell Precursor Cells As Potential Diagnostic and Therapeutic Biomarker in Patients with WHIM Syndrome
Authors: Ulrich Salzer, Christoph B. Geier, Maryssa Ellison, Melis Yilmaz, Caroline von Spee-Mayer, Carsten Speckmann, Stephan Ehl, Olaf Neth, Ana Pilar Garcia Garcia, Angela Deya Martinez, Laia Alsina, Katja Sockel, Catharina Schuetz, David E. Potts, Boglarka Ujhazi, Krisztian Csomos, Jolan E. Walter, Klaus Warnatz
Journal: Blood (2022)
Restless Legs Syndrome (RLS) in Patients (pts) with Polycythemia Vera (PV): Is Iron Deficiency (ID) the Only Culprit?
Authors: Duygu Seyhan Erdoğan, Gülçin Benbir Şenel, Ayşegül Gündüz, Beria Peren Uçar, Tuğrul Elverdi, Ayse Salihoglu, Muhlis Cem Ar, Şeniz Öngören, Zafer Başlar, Ahmet Emre Eşkazan
Journal: Blood (2022)
Post-Allogeneic Stem Cell Transplant Outcomes in Patients Treated with Hypomethylating Agent Plus Venetoclax Compared to CPX-351
Authors: Akriti G Jain, Somedeb Ball, Luis E.E. Aguirre, Andrew Kuykendall, Onyee Chan, Rami S. Komrokji, Eric Padron, David A. Sallman, Jeffrey E. Lancet, Asmita Mishra, Kendra Sweet
Journal: Blood (2022)
Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study
Authors: Florian H Heidel, Andrew Charles Perkins, Andreas Reiter, Carl C. Crodel, Caroline Hasselbalch Riley, María Teresa Gómez-Casares, Istvan Takacs, Heiko Becker, Thomas Lehmann, Olga Vinogradova, Kate Burbury, Alessandro M. Vannucchi, Vikas Gupta, Claire Harrison, Marielle Wondergem, Jean-Jacques Kiladjian, Grace Cleary, Angela Zhang, Bruyère Mahuzier, Jagannath Kota, Anirudh Prahallad, David M Ross
Journal: Blood (2022)
Prevalence and Impact of Potentially Inappropriate Medication Use on Post-Transplant Outcomes Among Older Adults with Plasma Cell Dyscrasias Receiving an Autologous Stem Cell Transplant
Authors: Nicole Watts, Courtney Hebert, Clare Ubersax, Deanna Clark, Gayathri Ravi, Susan Bal, Purnima Singh, Kelly N. Godby, Donna Salzman, Luciano J. Costa, Grant Williams, Smita Bhatia, Smith Giri
Journal: Blood (2022)
Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience
Authors: Vincent Marmouset, Justine Decroocq, Sylvain Garciaz, Gabriel Etienne, Amine Belhabri, Sarah Bertoli, Lauris Gastaud, Celestine Simand, Sylvain Chantepie, Madalina Uzunov, Alexis Genthon, Celine Berthon, Edmond Chiche, Pierre-Yves Dumas, Jacques Vargaftig, Géraldine Salmeron, Emilie Lemasle, Emmanuelle Tavernier, Jeremy Delage, Marion Loirat, Nadine Morineau, Felix Blanc-Durand, Patricia Pautier, Veronique Vergé, Nathalie Auger, Myrtille Thomas, Laetitia Stefani, Marion Lepelley, Thomas Boyer, Sylvain Thepot, Marie-Pierre Gourin, Pascal Bourquard, Matthieu Duchmann, Pierre Morice, Mauricette Michallet, Lionel Ades, Pierre Fenaux, Christian Recher, Hervé Dombret, Arnaud Pages, Christophe Marzac, Alexandra Leary, Jean-Baptiste Micol
Journal: Blood (2022)
Validation of the Molecular International Prognostic Scoring System in Patients with Myelodysplastic Syndrome
Authors: Tariq Kewan, Waled Bahaj, Mai Aly, Arda Durmaz, Olisaemeka Ogbue, Hetty E. Carraway, Abhay Singh Singh, Suresh Kumar Balasubramanian, Mikkael A. Sekeres, Valeria Visconte, Carmelo Gurnari, Jaroslaw P. Maciejewski
Journal: Blood (2022)
The diagnosis of severe combined immunodeficiency (SCID): The Primary Immune Deficiency Treatment Consortium (PIDTC) 2022 Definitions
Authors: Christopher C. Dvorak, Elie Haddad, Jennifer Heimall, Elizabeth Dunn, Rebecca H. Buckley, Donald B. Kohn, Morton J. Cowan, Sung-Yun Pai, Linda M. Griffith, Geoffrey D.E. Cuvelier, Hesham Eissa, Ami J. Shah, Richard J. O’Reilly, Michael A. Pulsipher, Nicola A.M. Wright, Roshini S. Abraham, Lisa Forbes Satter, Luigi D. Notarangelo, Jennifer M. Puck
Journal: Journal of Allergy and Clinical Immunology (2022)

Severe combined immunodeficiency (SCID) results from defects in the differentiation of hematopoietic stem cells into mature T lymphocytes, with additional lymphoid lineages affected in particular genotypes. In 2014, the Primary Immune Deficiency Treatment Consortium published criteria for diagnosing SCID, which are now revised to incorporate contemporary approaches. Patients with typical SCID must have less than 0.05 × 10
The diagnosis of severe combined immunodeficiency: Implementation of the PIDTC 2022 Definitions
Authors: Christopher C. Dvorak, Elie Haddad, Jennifer Heimall, Elizabeth Dunn, Morton J. Cowan, Sung-Yun Pai, Neena Kapoor, Lisa Forbes Satter, Rebecca H. Buckley, Richard J. O’Reilly, Sharat Chandra, Jeffrey J. Bednarski, Olatundun Williams, Ahmad Rayes, Theodore B. Moore, Christen L. Ebens, Blachy J. Davila Saldana, Aleksandra Petrovic, Deepak Chellapandian, Geoffrey D.E. Cuvelier, Mark T. Vander Lugt, Emi H. Caywood, Shanmuganathan Chandrakasan, Hesham Eissa, Frederick D. Goldman, Evan Shereck, Victor M. Aquino, Kenneth B. Desantes, Lisa M. Madden, Holly K. Miller, Lolie Yu, Larisa Broglie, Alfred Gillio, Ami J. Shah, Alan P. Knutsen, Jeffrey P. Andolina, Avni Y. Joshi, Paul Szabolcs, Malika Kapadia, Caridad A. Martinez, Roberta E. Parrot, Kathleen E. Sullivan, Susan E. Prockop, Roshini S. Abraham, Monica S. Thakar, Jennifer W. Leiding, Donald B. Kohn, Michael A. Pulsipher, Linda M. Griffith, Luigi D. Notarangelo, Jennifer M. Puck
Journal: Journal of Allergy and Clinical Immunology (2022)
Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Review for the American College of Physicians
Authors: Isolde Sommer, Andreea Dobrescu, Dominic Ledinger, Isabel Moser, Kylie Thaler, Emma Persad, Martin Fangmeyer, Robert Emprechtinger, Irma Klerings, Gerald Gartlehner
Journal: Annals of Internal Medicine (2022)

Clinicians and patients want to know the benefits and harms of outpatient treatment options for SARS-CoV-2 infection. To assess the benefits and harms of 12 different COVID-19 treatments in the outpatient setting. Epistemonikos COVID-19 L·OVE Platform, searched on 4 April 2022. Two reviewers independently screened abstracts and full texts against a priori-defined criteria. Randomized controlled trials (RCTs) that compared COVID-19 treatments in adult outpatients with confirmed SARS-CoV-2 infection were included. One reviewer extracted data and assessed risk of bias and certainty of evidence (COE). A second reviewer verified data abstraction and assessments. The 26 included studies collected data before the emergence of the Omicron variant. Nirmatrelvir-ritonavir and casirivimab-imdevimab probably reduced hospitalizations (1% vs. 6% [1 RCT] and 1% vs. 4% [1 RCT], respectively; moderate COE). Nirmatrelvir-ritonavir probably reduced all-cause mortality (0% vs. 1% [1 RCT]; moderate COE), and regdanvimab probably improved recovery (87% vs. 72% [1 RCT]; moderate COE). Casirivimab-imdevimab reduced time to recovery by a median difference of 4 days (10 vs. 14 median days [1 RCT]; high COE). Molnupiravir may reduce all-cause mortality, sotrovimab may reduce hospitalization, and remdesivir may improve recovery (low COE). Lopinavir-ritonavir and azithromycin may have increased harms, and hydroxychloroquine may result in lower recovery rates (low COE). Other treatments had insufficient evidence or no statistical difference in efficacy and safety versus placebo. Many outcomes had few events and small samples. Some antiviral medications and monoclonal antibodies may improve outcomes for outpatients with mild to moderate COVID-19. However, the generalizability of the findings to the currently dominant Omicron variant is limited. American College of Physicians. (PROSPERO: CRD42022323440).
Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial
Authors: Gail E. Potter, Tyler Bonnett, Kevin Rubenstein, David A. Lindholm, Rekha R. Rapaka, Sarah B. Doernberg, David C. Lye, Richard A. Mularski, Noreen A. Hynes, Susan Kline, Catharine I. Paules, Cameron R. Wolfe, Maria G. Frank, Nadine G. Rouphael, Gregory A. Deye, Daniel A. Sweeney, Rhonda E. Colombo, Richard T. Davey, Aneesh K. Mehta, Jennifer A. Whitaker, Jose G. Castro, Alpesh N. Amin, Christopher J. Colombo, Corri B. Levine, Mamta K. Jain, Ryan C. Maves, Vincent C. Marconi, Robert Grossberg, Sameh Hozayen, Timothy H. Burgess, Robert L. Atmar, Anuradha Ganesan, Carlos A. Gomez, Constance A. Benson, Diego Lopez de Castilla, Neera Ahuja, Sarah L. George, Seema U. Nayak, Stuart H. Cohen, Tahaniyat Lalani, William R. Short, Nathaniel Erdmann, Kay M. Tomashek, Pablo Tebas
Journal: Annals of Internal Medicine (2022)

The COVID-19 standard of care (SOC) evolved rapidly during 2020 and 2021, but its cumulative effect over time is unclear.
Major Update 2: Antibody Response and Risk for Reinfection After SARS-CoV-2 Infection—Final Update of a Living, Rapid Review
Authors: Haley K. Holmer, Katherine Mackey, Celia V. Fiordalisi, Mark Helfand
Journal: Annals of Internal Medicine (2022)

The durability of the antibody response after SARS-CoV-2 infection and the role of antibodies in protection against reinfection are unclear.To synthesize evidence on the SARS-CoV-2 antibody response and reinfection risk with a focus on gaps identified in our prior reports.MEDLINE (Ovid), EMBASE, CINAHL, World Health Organization Research Database, and reference lists from 16 December 2021 through 8 July 2022, with surveillance through 22 August 2022.English-language, cohort studies evaluating IgG antibody duration at least 12 months after SARS-CoV-2 infection, the antibody response among immunocompromised adults, predictors of nonseroconversion, and reinfection risk.Two investigators sequentially extracted study data and rated quality.Most adults had IgG antibodies after SARS-CoV-2 infection at time points greater than 12 months (low strength of evidence [SoE]). Although most immunocompromised adults develop antibodies, the overall proportion with antibodies is lower compared with immunocompetent adults (moderate SoE for organ transplant patients and low SoE for patients with cancer or HIV). Prior infection provided substantial, sustained protection against symptomatic reinfection with the Delta variant (high SoE) and reduced the risk for severe disease due to Omicron variants (moderate SoE). Prior infection was less protective against reinfection with Omicron overall (moderate SoE), but protection from earlier variants waned rapidly (low SoE).Single review for abstract screening and sequential review for study selection, data abstraction, and quality assessment.Evidence for a sustained antibody response to SARS-CoV-2 infection is considerable for both Delta and Omicron variants. Prior infection protected against reinfection with both variants, but, for Omicron, protection was weaker and waned rapidly. This information may have limited clinical applicability as new variants emerge.Agency for Healthcare Research and Quality. (PROSPERO: CRD42020207098).
Differential Fibrinolysis Profile in COVID-19 Patients Dependent on Immunosuppressive Treatment Regimen: A Nested Case-Control Study
Authors: Magdolna Nagy, Joep Schellens, Anne-Marije Hulshof, Frank van Rosmalen, Rene van Oerle, Thijs T.W. van Herpt, Teba Alnima, Mark Mulder, Dave Hellenbrand, Hugo ten Cate, Yvonne M.C. Henskens, Bas C.T. Van Bussel, Henri M.H. Spronk
Journal: Blood (2022)
Health-Related Quality of Life, Disease Impacts, and Health Equity Concerns in Adults with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises: Preliminary Results from a Global Longitudinal Survey
Authors: Jennifer Drahos, Adriana Boateng-Kuffour, Melanie Calvert, Ashley Valentine, Anthony Mason, Zahra Pakbaz, Fikret Kaan Oran, Kamran Iqbal, Farrukh Shah, Nanxin Li, Antony P. Martin
Journal: Blood (2022)
CAR.CD123-NK Cells Have an Equally Effective but Safer Off-Tumor/on-Target Profile As Compared to CARCD123-T Cells for the Treatment of Acute Myeloid Leukaemia
Authors: Simona Caruso, Concetta Quintarelli, Biagio De Angelis, Francesca Del Bufalo, Roselia Ciccone, Samantha Donsante, Gabriele Volpe, Simona Manni, Marika Guercio, Michele Pezzella, Laura Iaffaldano, Domenico Alessandro Silvestris, Matilde Sinibaldi, Stefano Di Cecca, Angela Pitisci, Enrico Velardi, Pietro Merli, Mattia Algeri, Mariachiara Lodi, Valeria Paganelli, Marta Serafini, Mara Riminucci, Franco Locatelli
Journal: Blood (2022)
The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy
Authors: Tracy Murphy, Stanley W.K. Ng, Ian King, Tong Zhang, Andrea Arruda, Jaime Claudio, Kristele Pan, Chantal Rockwell, Zhibin Lu, Natalie Stickle, Carl Virtanen, Vikas Gupta, Dawn Maze, Caroline McNamara, Aaron D. Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Dina Khalaf, Brian Leber, Mitchell Sabloff, Anne Tierens, Mark D. Minden, Tracy L. Stockley, Steven Chan, Jean C.Y. Wang
Journal: Blood (2022)
The Impact of Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation on Survival Outcomes in Patients Diagnosed with Acute Myeloid Leukemia and Persistent Measurable Residual Disease: A Retrospective Cohort
Authors: Racha Khodr, Ammar Zaherddine, Maya Charafeddine, Nour Moukalled, Jean El-Cheikh, Ali Bazarbachi, Iman Abou Dalle
Journal: Blood (2022)
Systematic Review and Meta- Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Gastric and Gastro-Esophageal Junction (GEJ) Cancers Receiving Chemotherapy
Authors: Kyaw Zin Thein, Thura Win Htut, Myat Min Han, Yin Mon Myat, Myint Aung Win, Ei Moe Phyu, Thein H. Oo
Journal: Blood (2022)
<i>Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy</i>
Authors: Jorge M. Ramos Perez, Jose Tinajero, Dat Ngo, Jianying Zhang, Paul B. Koller, Vaibhav Agrawal, Hoda Pourhassan, Monzr M. Al Malki, Amandeep Salhotra, Haris Ali, Ahmed Aribi, Karamjeet S. Sandhu, Shukaib Arslan, Salman Otoukesh, Idoroenyi Amanam, Andrew S. Artz, Pamela S. Becker, Forrest M. Stewart, Eileen P. Smith, Peter Curtin, Stephen J Forman, Ryotaro Nakamura, Vinod A. Pullarkat, Guido Marcucci, Anthony S. Stein, Ibrahim Aldoss, Brian J Ball
Journal: Blood (2022)
Pharmacological Characterization of JNJ-75276617, a Menin-KMT2A Inhibitor, As Targeted Treatment for KMT2A-Altered and NPM1-Mutant Acute Leukemia
Authors: Min Chul Kwon, Olivier Querolle, Xuedong Dai, Jan Willem Thuring, Tinne Verhulst, Ann Marien, Dries Goffin, Wei Cai, Vikki Keersmaekers, Filmon Eyassu, Karin Verstraeten, Sara El Ashkar, Shanna M Hogeling, Frank Jacob, Petra Vinken, Nicolas Darville, Vineet Pande, Daniel Krosky, Gregor Urbanietz, Bie Verbist, Lucille A. Ferrante, Christina Diane Drenberg, David Wilson, Ricardo M. Attar, Jan Jacob Schuringa, Nikki Daskalakis, Kathryn Packman, Christine Pietsch, Yusri Elsayed, Ulrike Philippar
Journal: Blood (2022)
Zanubrutinib Plus Ixazomib and Dexamethasone for Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Prospective, Phase II Study
Authors: Ying Yu, ShuHua Yi, Xiong Wenjie, Tingyu Wang, Yuting Yan, Wei Liu, Weiwei Sui, Gang An, Yan Xu, Huimin Liu, Wenyang Huang, Dehui Zou, Lugui Qiu
Journal: Blood (2022)
Combination of 5-Azacytidine and Pegifna Is Able to Overcome Resistance in <i>JAK2</i>-V617F Positive MPN with Loss of <i>Dnmt3a</i>
Authors: Melissa Lock, Damien Luque Paz, Nils Hansen, Tiago Almeida Fonseca, MARC Usart, Shivam Rai, Hui Hao-Shen, Gabriele Mild, Stephan Dirnhofer, Radek C. Skoda, Jan Stetka
Journal: Blood (2022)
Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib
Authors: Jessica M. Stempel, Rong Wang, Rory Michael Shallis, Scott F. Huntington, Amer M. Zeidan, Natalia Neparidze, Mengyang Di, Xiaomei Ma, Nikolai A. Podoltsev
Journal: Blood (2022)
Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak’s Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003
Authors: Wei Shen Tan, Connor Mustard, John D. Kelly
Journal: European Urology (2022)
Targeting Molecular Remission with Donor Lymphocyte Infusions Shows Excellent Outcomes for Persistent or Relapsed Myelofibrosis after Stem Cell Transplantation
Authors: Nico Gagelmann, Anita Badbaran, Christine Wolschke, Raissa Adjallé, Dietlinde Janson, Carolina Berger, Evgeny Klyuchnikov, Boris Fehse, Francis A. Ayuk, Nicolaus Kroeger
Journal: Blood (2022)
ACC1 Inhibition Enhances Treg Gvhd Treatment Efficacy through Reciprocal Fatty-Acid Synthesis and Oxidative Phosphorylation Regulation
Authors: Cameron McDonald-Hyman, Ethan Aquilar, Stephanie Rhee, Fathima Mohamed, Ewaldus Compeer, Michael Dustin, Keli Lee Hippen, Bruce R. Blazar
Journal: Blood (2022)
Retrospective Evaluation of Real-World Treatment Patterns in Patients with Mantle Cell Lymphoma - REALM in a Single Brazilian Center
Authors: Marcelo Bellesso, Rodrigo Santucci, Renato Torrescasana Centrone, Daniela Ferreira Dias, Mariana Nascimento Caiaffo Rodrigues, Luana Correa Travassos, Iohanã Gabriely Costa Oliveira, Tamyres Alves Gomes, Caroline Jorge Espadas, Joyce Barreto Marques da Rosa Ferreira, Bruno Santucci, Adelson Alves
Journal: Blood (2022)
LigandCD70.CAR As a Platform for Dual-Targeting CAR T Cells for Acute Myeloid Leukemia
Authors: Lauren Scherer, Candise Tat, Tim Sauer, Haruko Tashiro, Swati Naik, Mireya Paulina Velasquez, Stephen Gottschalk, Cliona M. Rooney, Malcolm K. Brenner, Bilal Omer
Journal: Blood (2022)